| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Calcitonin, eel TFA targets the calcitonin receptor 2 (CTR2), a G protein-coupled receptor. It binds to CTR2 with very high affinity, exhibiting a Ki of 0.01 nM in radioligand binding assays, which is significantly higher than human (2.95 nM), porcine (0.44 nM), or rat (5.89 nM) calcitonin. The thyroid hormone peptide contributes to the regulation of calcium homeostasis by inhibiting osteoclast-mediated bone resorption and promoting renal calcium excretion.
|
|---|---|
| ln Vitro |
When compared to salmon calcitonin, eel calcitonin in cultured anterior pituitary cells efficiently promotes a concentration-dependent activation of phosphoinositide hydrolysis and boosts prolactin release[1]. When thyrotropin releasing hormone (TRH) is activated, calcitonin, eel, has no effect on the suppression of prolactin production [1].
In vitro, calcitonin, eel effectively induces a concentration-dependent stimulation of phosphoinositide hydrolysis and stimulates prolactin release compared to salmon calcitonin in cultured anterior pituitary cells. It is inactive on the inhibition of prolactin release under thyrotropin releasing hormone (TRH) stimulated conditions. The peptide also has effects on osteoblastic function, as studied in UMR-106 cells. |
| ln Vivo |
In vivo, calcitonin, eel is used in the research of postmenopausal osteoporosis to study bone density and mineral homeostasis. It acts to reduce blood calcium ions, opposing the effects of parathyroid hormone. The calcitonin assay is also used in identifying patients with nodular thyroid diseases, particularly in making an early diagnosis of medullary carcinoma of the thyroid. Eel calcitonin potently influences bone metabolism in animal models.
|
| Enzyme Assay |
Binding affinity of calcitonin, eel for the calcitonin receptor is determined using radioligand binding assays on membrane preparations from cells expressing recombinant human or animal CTR2. Various concentrations of the peptide are incubated with a fixed concentration of a radiolabeled calcitonin tracer (e.g., [¹2⁵I]-labeled calcitonin) in a binding buffer. After incubation, bound and free radioligands are separated by filtration or centrifugation, and radioactivity is measured. Ki values are calculated from competition binding curves.
|
| Cell Assay |
Cellular assays for calcitonin, eel are performed using cultured anterior pituitary cells or osteoblastic UMR-106 cells. Cells are treated with various concentrations of the peptide for defined periods. Endpoints include measurement of phosphoinositide hydrolysis by quantifying inositol phosphate accumulation, assessment of prolactin release by ELISA or RIA, and evaluation of osteoblast function by measuring alkaline phosphatase activity or calcium deposition. The cAMP response can also be measured, as CTR2 couples to Gs proteins.
|
| Animal Protocol |
In vivo studies are typically conducted in rodent models of osteoporosis, such as ovariectomized rats. Calcitonin, eel TFA is administered via subcutaneous injection at doses ranging from 1 to 50 IU/kg daily or every other day for 4-12 weeks. Endpoints include measurement of serum calcium and phosphorus levels, assessment of bone mineral density (BMD) by DEXA or micro-CT, histomorphometric analysis of bone sections, and measurement of bone turnover markers (e.g., P1NP, NTX) in serum.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for calcitonin, eel are not extensively detailed in standard product literature. As a 32-amino acid peptide, its PK profile is characterized by rapid absorption following subcutaneous or intramuscular injection, with a half-life typically ranging from 15 to 30 minutes. It undergoes proteolytic degradation in the kidneys and is not orally bioavailable. The TFA salt form enhances solubility for research applications. Metabolism primarily occurs in the kidneys via proteolytic enzymes.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicological data for calcitonin, eel TFA are not provided in standard product literature, but the peptide has a well-established safety profile in animal and clinical research settings. As a thyroid hormone peptide, it is generally well-tolerated at research-use doses. Potential side effects at high doses may include nausea, flushing, and injection site reactions. For laboratory use, standard chemical safety precautions for handling peptides should be followed.
|
| References |
[1]. Sortino MA, et al. Comparative effects of eel calcitonin, salmon calcitonin and [Asu1,7]eel calcitonin on hypophyseal and osteoblastic function. Gynecol Endocrinol. 1993 Jun;7(2):89-96.
|
| Additional Infomation |
Calcitonin, eel TFA (Thyrocalcitonin eel TFA) has a molecular formula of C14₈H242F3N43O4₉S2 and a molecular weight of 3405.96 (free base). The peptide appears as a white to off-white solid powder with a purity of 98.79%. It is stored at -20degC or -80degC, sealed, and away from moisture. The peptide differs from salmon calcitonin by three amino acid residues at positions 26, 27, and 29, affecting receptor binding characteristics.
|
| Molecular Formula |
C148H242F3N43O49S2
|
|---|---|
| Molecular Weight |
3528.89
|
| Related CAS # |
Calcitonin, eel;57014-02-5
|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.2834 mL | 1.4169 mL | 2.8338 mL | |
| 5 mM | 0.0567 mL | 0.2834 mL | 0.5668 mL | |
| 10 mM | 0.0283 mL | 0.1417 mL | 0.2834 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
